Human papillomavirus genotype and prognosis of invasive cervical cancer: A nationwide cohort study.

Authors

null

Jiayao Lei

Karolinska Institutet, Stockholm, Sweden

Jiayao Lei , Alexander Ploner , Camilla Lagheden , Carina Eklund , Sara Nordqvist Kleppe , Bengt Andrae , Klara Miriam Elfström , Joakim Dillner , Pär Sparén , Karin Sundström

Organizations

Karolinska Institutet, Stockholm, Sweden, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, Center for Research and Development, Uppsala University/County Council of Gavleborg, Gavle, Sweden, Karolinska University Hospital, Solna, Sweden

Research Funding

Other Foundation

Background: The role of human papillomavirus (HPV) in development from oncogenic infection to invasive cervical cancer (ICC) has been well established. However, the association of HPV genotypes and prognosis of ICC is controversial. Methods: We identified all ICC diagnosed in Sweden during the years 2002-2011 (4254 confirmed cases after clinical and histo-pathological review), requested all archival formalin-fixed, paraffin-embedded blocks and subjected them to comprehensive HPV genotyping. Twenty out of twenty-five archives agreed to the study, contributing a total of 2845 confirmed cases with valid HPV results. Cases were followed up from date of cancer diagnosis to 31 December, 2015, migration from Sweden, or death; whichever occurred first. Five-year relative survival ratios (RSRs) were calculated and excess hazard ratios (EHRs) with 95% confidence intervals (CIs) were estimated using Poisson regression. Results: HPV was detected in 2365 tumors (83.1% of all cases). The five-year RSR by tumor HPV status was 0.54 (HPV negative), 0.76 (HPV16 positive), 0.73 (HPV18 positive), 0.72 (other high-risk HPV positive) and 0.56 (low-risk HPV positive) compared to the age-matched general female population. Compared to cases with HPV-negative tumor, a significantly lower excess mortality was seen if the tumor was positive for HPV16 (EHR:0.54, 95% CI 0.44-0.65), other high-risk HPV (EHR:0.47, 95% CI 0.37-0.60), and low-risk HPV (EHR:0.48, 95% CI 0.32-0.74), after adjustment for age, time since cancer diagnosis, International Federation of Gynecology and Obstetrics (FIGO) stage, educational level and histology. However, the mortality among women with HPV18 positive tumors were not statistically significantly different from cases with HPV-negative tumors. In women with a single HPV infection of either HPV16 or HPV18, those with HPV18-positive tumors had 56% (EHR:1.56, 95% CI: 1.13-1.97) higher excess mortality compared to women with HPV16-positive tumors. Conclusions: HPV genotype in cervical cancer tumor is associated with prognosis of ICC. Single HPV18 positivity indicated a poorer prognosis than single HPV16 positivity. This could add information of value beyond the established clinical prognostic factors for women diagnosed with ICC.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Cervical Cancer

Citation

J Clin Oncol 37, 2019 (suppl; abstr 5525)

DOI

10.1200/JCO.2019.37.15_suppl.5525

Abstract #

5525

Poster Bd #

348

Abstract Disclosures

Similar Abstracts

First Author: Abdullah Islam Abdelaziz

First Author: Jurema Telles O. Lima

Abstract

2022 ASCO Annual Meeting

Multi-omics characterization of productive HPV integration in cervical cancer.

First Author: Chaoyang Sun

Abstract

2024 ASCO Annual Meeting

Cancer in Southeast Asia: A comparative analysis of 2022 incidence and mortality data.

First Author: Edward Christopher Christopher Dee